These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 38613811

  • 1. Neutropenia Occurs More Often Under Carbimazole than Under Methimazole Treatment in Pediatric Graves' Disease Patients.
    Schempp V, Cebeci AN, Reinauer C, Woelfle J, Dörr HG, Roosen MT, Gohlke J, Gohlke B.
    Thyroid; 2024 Jun; 34(6):735-743. PubMed ID: 38613811
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily.
    Takata K, Kubota S, Fukata S, Kudo T, Nishihara E, Ito M, Amino N, Miyauchi A.
    Thyroid; 2009 Jun; 19(6):559-63. PubMed ID: 19445623
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK, Yoo WS, Kim DW, Chung HK.
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [Abstract] [Full Text] [Related]

  • 6. Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications.
    Harvengt J, Boizeau P, Chevenne D, Zenaty D, Paulsen A, Simon D, Guilmin Crepon S, Alberti C, Carel JC, Léger J.
    Eur J Endocrinol; 2015 Jun; 172(6):715-23. PubMed ID: 25766047
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism.
    Sato S, Noh JY, Sato S, Suzuki M, Yasuda S, Matsumoto M, Kunii Y, Mukasa K, Sugino K, Ito K, Nagataki S, Taniyama M.
    Thyroid; 2015 Jan; 25(1):43-50. PubMed ID: 25178068
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience.
    Bayramoğlu E, Elmaogulları S, Sagsak E, Aycan Z.
    J Pediatr Endocrinol Metab; 2019 Apr 24; 32(4):341-346. PubMed ID: 30862763
    [Abstract] [Full Text] [Related]

  • 11. Substituting Potassium Iodide for Methimazole as the Treatment for Graves' Disease During the First Trimester May Reduce the Incidence of Congenital Anomalies: A Retrospective Study at a Single Medical Institution in Japan.
    Yoshihara A, Noh JY, Watanabe N, Mukasa K, Ohye H, Suzuki M, Matsumoto M, Kunii Y, Suzuki N, Kameda T, Iwaku K, Kobayashi S, Sugino K, Ito K.
    Thyroid; 2015 Oct 24; 25(10):1155-61. PubMed ID: 26222916
    [Abstract] [Full Text] [Related]

  • 12. "Block-and-replace" treatment in Graves' disease: experience in a cohort of pediatric patients.
    Vigone MC, Peroni E, Di Frenna M, Mora S, Barera G, Weber G.
    J Endocrinol Invest; 2020 May 24; 43(5):595-600. PubMed ID: 31713721
    [Abstract] [Full Text] [Related]

  • 13. Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease.
    Kawakami-Tani T, Fukawa E, Tanaka H, Abe Y, Makino I.
    Metabolism; 1997 Oct 24; 46(10):1184-8. PubMed ID: 9322804
    [Abstract] [Full Text] [Related]

  • 14. The prevalence of transient thyrotoxicosis after antithyroid drug therapy in patients with Graves' disease.
    Kubota S, Takata K, Arishima T, Ohye H, Nishihara E, Kudo T, Ito M, Fukata S, Amino N, Miyauchi A.
    Thyroid; 2008 Jan 24; 18(1):63-6. PubMed ID: 18302519
    [Abstract] [Full Text] [Related]

  • 15. In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis.
    Wall JR, Fang SL, Kuroki T, Ingbar SH, Braverman LE.
    J Clin Endocrinol Metab; 1984 May 24; 58(5):868-72. PubMed ID: 6200492
    [Abstract] [Full Text] [Related]

  • 16. Incidence of and Risk Factors for Neonatal Hypothyroidism Among Women with Graves' Disease Treated with Antithyroid Drugs Until Delivery.
    Yoshihara A, Noh JY, Inoue K, Watanabe N, Fukushita M, Matsumoto M, Suzuki N, Suzuki A, Kinoshita A, Yoshimura R, Aida A, Imai H, Hiruma S, Sugino K, Ito K.
    Thyroid; 2023 Mar 24; 33(3):373-379. PubMed ID: 36680759
    [Abstract] [Full Text] [Related]

  • 17. T4 but not T3 administration is associated with increased recurrence of Graves' disease after successful medical therapy.
    Mastorakos G, Doufas AG, Mantzos E, Mantzos J, Koutras DA.
    J Endocrinol Invest; 2003 Oct 24; 26(10):979-84. PubMed ID: 14759070
    [Abstract] [Full Text] [Related]

  • 18. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease.
    Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N.
    J Clin Endocrinol Metab; 2007 Jun 24; 92(6):2157-62. PubMed ID: 17389704
    [Abstract] [Full Text] [Related]

  • 19. Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial.
    Leo M, Bartalena L, Rotondo Dottore G, Piantanida E, Premoli P, Ionni I, Di Cera M, Masiello E, Sassi L, Tanda ML, Latrofa F, Vitti P, Marcocci C, Marinò M.
    J Endocrinol Invest; 2017 Mar 24; 40(3):281-287. PubMed ID: 27734319
    [Abstract] [Full Text] [Related]

  • 20. Characteristics of agranulocytosis as an adverse effect of antithyroid drugs in the second or later course of treatment.
    Kobayashi S, Noh JY, Mukasa K, Kunii Y, Watanabe N, Matsumoto M, Ohye H, Suzuki M, Yoshihara A, Iwaku K, Sugino K, Ito K.
    Thyroid; 2014 May 24; 24(5):796-801. PubMed ID: 24341564
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.